Application of FDG-PET in cervical cancer and endometrial cancer: utility and future prospects.

Positron-emission tomography (PET), a diagnostic imaging technique using an agent labeled with a positron-emitting radionuclide, may facilitate improved diagnosis and treatment in gynecological fields. A combined PET/computerized tomography (CT) scan can identify the precise anatomical location of a lesion based on accumulation of (18)F-fluoro-D-glucose (FDG). FDG-PET and PET/CT have been used for detecting metastatic lesions and predicting prognosis in uterine cancer. PET has higher reliability in diagnosing lymph node metastases of uterine cancer than CT or MRI, and is considered most useful among non-invasive diagnostic imaging methods. Accumulation of FDG in lesions is indicative of a poor prognosis. Due to its limited spatial resolution, PET is not suitable has lower utility for detecting small lesions, and is not suitable for early-stage screening, and diagnosing primary lesions. Further improvements in diagnostic technology, including PET/MRI, investigation of new positron tracers, and analysis of data from various combinations of tracers are likely to make PET particularly useful for diagnosis and therapeutic strategy planning.

[1]  K. Sugimura,et al.  Performance of Integrated FDG-PET/Contrast-enhanced CT in the Diagnosis of Recurrent Pancreatic Cancer: Comparison with Integrated FDG-PET/Non-contrast-enhanced CT and Enhanced CT , 2010, Molecular Imaging and Biology.

[2]  Eiji Sugiyama,et al.  Development of a flexible optical fiber based high resolution integrated PET∕MRI system. , 2011, Medical physics.

[3]  V. Torri,et al.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[4]  T. Yen,et al.  18F-FDG PET in the management of endometrial cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Matthias Hofmann,et al.  Hybrid PET/MRI of Intracranial Masses: Initial Experiences and Comparison to PET/CT , 2010, The Journal of Nuclear Medicine.

[6]  K. Togashi,et al.  Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer , 2003, Annals of nuclear medicine.

[7]  E. Mittra,et al.  Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  T. Yen,et al.  Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  P. Grigsby,et al.  Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. , 2004, Gynecologic oncology.

[10]  E. Glatstein,et al.  F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy , 2007 .

[11]  F. Fazio,et al.  Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. , 2006, Radiology.

[12]  P. Grigsby,et al.  FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. , 2002, International journal of radiation oncology, biology, physics.

[13]  Y. Nishiyama,et al.  Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  S. Matsumoto,et al.  Comparison of quantitatively analyzed dynamic area-detector CT using various mathematic methods with FDG PET/CT in management of solitary pulmonary nodules. , 2013, AJR. American journal of roentgenology.

[15]  Bernd J. Pichler,et al.  Feasibility of simultaneous PET/MR imaging in the head and upper neck area , 2011, European Radiology.

[16]  S. Nishizawa,et al.  Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  P. Grigsby,et al.  The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival , 2007, Cancer.

[18]  D. Matchar,et al.  FDG-PET for management of cervical and ovarian cancer. , 2005, Gynecologic oncology.

[19]  H. Kitchener.  Management of endometrial cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  Bernd J. Pichler,et al.  PET/MRI hybrid imaging: devices and initial results , 2008, European Radiology.

[21]  M. Parmar,et al.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.

[22]  F. Lawton.  The management of endometrial cancer , 1997 .

[23]  C. Haie-meder,et al.  Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Ş. Tınar,et al.  Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings. , 2008, Gynecologic oncology.

[25]  D. Grisaru,et al.  Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  R. Shah,et al.  Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[27]  S. Higashiyama,et al.  A case of cavernous hemangioma in which malignancy was preoperatively excluded by FDG-PET , 2008, Annals of nuclear medicine.

[28]  P. Grigsby,et al.  Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Sugimura,et al.  Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. , 2008, AJR. American journal of roentgenology.

[30]  R. Coleman,et al.  Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry , 2008, Journal of Nuclear Medicine.

[31]  Yong-Man Kim,et al.  Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. , 2008, Gynecologic oncology.

[32]  J Aoki,et al.  Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. , 1999, Nuclear medicine communications.

[33]  K. Sugimura,et al.  Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  M R Segal,et al.  Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. , 1997, JAMA.

[35]  H. Chung,et al.  Post-treatment [18F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  C. Ottosen,et al.  The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. , 2007, Gynecologic oncology.

[37]  R. Hustinx,et al.  Usefulness of 18F-FDG PET in the post-therapy surveillance of endometrial carcinoma , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  Yiyan Liu.  Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls , 2009, Annals of nuclear medicine.

[39]  E. Hoffman,et al.  Application of annihilation coincidence detection to transaxial reconstruction tomography. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  M. Shida,et al.  F-18 fluorodeoxyglucose uptake in leiomyomatous uterus , 2006, International Journal of Gynecologic Cancer.

[41]  Paul Kinahan,et al.  Attenuation correction for a combined 3D PET/CT scanner. , 1998, Medical physics.

[42]  K. Sugimura,et al.  Spectrum of FDG PET/CT findings of uterine tumors. , 2010, AJR. American journal of roentgenology.

[43]  G. Antoch,et al.  Oncologic PET/MRI, Part 1: Tumors of the Brain, Head and Neck, Chest, Abdomen, and Pelvis , 2012, The Journal of Nuclear Medicine.

[44]  H. Okazawa,et al.  18F-FES and 18F-FDG PET for Differential Diagnosis and Quantitative Evaluation of Mesenchymal Uterine Tumors: Correlation with Immunohistochemical Analysis , 2013, The Journal of Nuclear Medicine.

[45]  R. Kimmig,et al.  Comparison of the Diagnostic Value of FDG-PET/CT and Axillary Ultrasound for the Detection of Lymph Node Metastases in Breast Cancer Patients , 2012, Acta radiologica.

[46]  Seok-ki Kim,et al.  Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma , 2006, Cancer.

[47]  K. Sugimura,et al.  Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  Y. Fujibayashi,et al.  Functional Images Reflect Aggressiveness of Endometrial Carcinoma: Estrogen Receptor Expression Combined with 18F-FDG PET , 2009, Journal of Nuclear Medicine.

[49]  T. Yen,et al.  Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases. , 2008, Gynecologic oncology.